Search results
Results from the WOW.Com Content Network
An investigation by the Democratic-led Senate Committee on Health, Education, Labor and Pensions noted AstraZeneca charges $645 in the U.S. for the same inhaler it charges $49 for in the U.K. Teva ...
(Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker ...
WASHINGTON (Reuters) -President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to ...
(Reuters) -AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, starting June, following a similar move by rival ...
Mar. 17—Drugmaker Boehringer Ingelheim said that it would cap patient copays for all of its inhalers at $35 starting on June 1. The company also announced that it will lower the list price of ...
For premium support please call: 800-290-4726 more ways to reach us
The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...
(Reuters) -The Trump administration has withdrawn a plan to ban menthol cigarettes in the U.S., in a setback to health regulators and activists. The Food and Drug Administration had in April 2022 ...